Lung Cancer

Lung Cancer Isotype

Non-Small Cell Lung Cancer: Squamous Cell Carcinoma; Adenocarcinoma; Large-Cell Lung Carcinoma

Small-Cell Lung Cancer: Small-Cell Lung Cancer

Chemotherapy

Platinum-based: Nedaplatin; Cisplatin; Carboplatin; Lobaplatin

Alkaloids: Nab-Paclitaxel; Vinorelbine ditartrate; Paclitaxel; Docetaxel

Antimetabolites: Pemetrexed; Gemcitabine; Methotrexate

TOPO Inhibitors: Irinotecan; Etoposide; Topotecan; Doxorubicin

Alkylating Agents: TMZ; Ifosfamide; Cyclophosphamide

Immune Checkpoint Inhibitors

PD-1: Cemiplimab; Pembrolizumab; Camrelizumab; Sintilimab; Nivolumab; Serplulimab

PD-L1: Avelumab; Atezolizumab; Durvalumab; Adebrelimab; Sugemalimab; Cosibelimab

CTLA-4: Ipilimumab; Tremelimumab

KRAS G12C-Targeted

ADC

c-Met: Telisotuzumab vedotin

HER3: Patritumab deruxtecan

HER2: Trastuzumab-deruxtecan; Trastuzumab-Emtansine（T-DM1）

TROP2: Sacituzumab-govitecan; Datopotamab deruxtecan

EGFR: Cetuximab-MMAE

ALK: MS4078

CEACAM5: Tusamitamab ravtansine

ROR2: Ozuriftamab vedotin

HER2-Targeted

Pan-HER TKIs: Afatinib; Neratinib; Dacomitinib

Selective HER2 TKIs: Pyrotinib dimaleate; Poziotinib; (S)-Sunvozertinib

Anti-HER2 Antibodies: Trastuzumab; Pertuzumab

ALK-Targeted

First-Generation ALK-TKIs ^[1]: PF-02341066

Second-Generation ALK-TKIs ^[1]: Ceritinib; Alectinib; Brigatinib; Ensartinib dihydrochloride

Third-Generation ALK-TKIs ^[1]: Lorlatinib

EGFR-Targeted

First-Generation EGFR-TKIs ^[2]: Erlotinib; Gefitinib; Lapatinib; Icotinib

Second-Generation EGFR-TKIs ^[2]: Afatinib; Dacomitinib; Neratinib; Poziotinib

Third-Generation EGFR-TKIs ^[3] ^[4]: AZD9291; Mobocertinib; Rociletinib; Olmutinib; Nazartinib; Furmonertinib Mesylate; Almonertinib; Lazertinib

Fourth-Generation EGFR-TKIs ^[3]: EAI045; BLU-945; CH7233163; TQB3804

Anti-EGFR Antibodies: Cetuximab; Panitumumab; Necitumumab

Anti-Angiogenesis

MET-Targeted

Type I MET-TKIs ^[5]: PF-02341066; Capmatinib; Tepotinib; Savolitinib

Type II MET-TKIs ^[5]: Cabozantinib; Merestinib

Type III MET-TKIs ^[5]: Tivantinib

ROS1-Targeted

First-Generation ROS1-TKIs ^[6]: PF-02341066

Second-Generation ROS1-TKIs ^[6]: Ceritinib; Repotrectinib

Third-Generation ROS1-TKIs ^[6]: Lorlatinib

BRAF-Targeted

First-Generation (Type I) BRAF Inhibitors ^[7]: PLX4032; Dabrafenib; LGX818

Next-Generation (Type II) BRAF Inhibitors ^[7]: AZ 628; LY3009120; Belvarafenib; CCT196969; Tovorafenib; Naporafenib; PLX7904; Plixorafenib

RET-Targeted

Selective RET Inhibitors: LOXO-292; Pralsetinib

Non-Selective RET Inhibitors: Cabozantinib; Vandetanib; E7080; Regorafenib

Compound Library

FDA-approved Anticancer Drug Library

Anti-cancer Compound Library

Anti-cancer Compound Library-Ⅱ

Anti-cancer Metabolism Compound Library

Cambridge Cancer Compound Library

FDA-approved Drug Library

References

https://pubmed.ncbi.nlm.nih.gov/33639216/
https://pubmed.ncbi.nlm.nih.gov/36768973/
https://pubmed.ncbi.nlm.nih.gov/37657684/
https://pubmed.ncbi.nlm.nih.gov/35445633/
https://pubmed.ncbi.nlm.nih.gov/31279006/
https://pubmed.ncbi.nlm.nih.gov/33743408/
https://pubmed.ncbi.nlm.nih.gov/36331404/